Remove BioTech Remove Drug Development Remove Industry Remove Life Science
article thumbnail

Accelerator Life Science Partners Launches Biotechnology Startup Company in Singapore with $16M in Series A Commitments

Digital Health Global

Our mission is to accelerate the commercialization of breakthrough innovations like the AUTAC platform for health impact, and we welcome Automera and ALSP to Singapore’s growing life sciences translational community.” We invest and partner with innovators, entrepreneurs, and founders to launch and grow global companies in Singapore.

article thumbnail

Koneksa Announces Expanded Partnership with SSI Strategy to Scale the Adoption of Digital Biomarkers in Clinical Trials

Digital Health Global

Koneksa’s digital biomarker solutions include an industry-leading platform that gives research sponsors and clinical sites the ability to seamlessly aggregate data in real-time from devices, ePROs, patient diaries, and clinical assessments to provide the full picture of an individual’s health.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Pharma IT and AI – 2024 Health IT Predictions

Healthcare IT Today

The excitement around new tools took hold of all industries in 2023, and the potential is expansive. The unification of technology, services and pharmacovigilance expertise in the coming year will further enunciate the industry’s focus on patient safety. Dave Latshaw, CEO at BioPhy 1.

article thumbnail

Let’s Save the Date and Make Patient Engagement Official in 2022

Society for Participatory Medicine

The same definition of patient engagement applies to industry, except that the interventions lead to more human centered design and value-based care. Healthcare stakeholders such as health systems, pharmaceutical companies, biotech and life sciences firms, and insurance companies serve patients as end users.

BioTech 107
article thumbnail

Aviceda Therapeutics Announces Strategic Partnership with Queen’s University Belfast (QUB)

Digital Health Global

–(BUSINESS WIRE)– Aviceda Therapeutics , a clinical-stage biotech company focused on developing next-generation immuno-modulators to treat diseases such as cancer, today announced a strategic partnership with the Patrick G Johnston Centre for Cancer Research at Queen’s University Belfast (Queen’s). CAMBRIDGE, Mass.–(BUSINESS

article thumbnail

Avilar Therapeutics Increases Financing to $75 Million to Advance Pipeline of Novel Extracellular Protein Degraders

Digital Health Global

Their expertise in company building, capital formation, and drug development will be a tremendous resource to Avilar as the innovation leader in the new field of extracellular protein degradation.” For more information, please visit www.avilar-tx.com and follow us on Twitter @Avilar_Tx and on LinkedIn.

article thumbnail

AstraZeneca launches Evinova, a health-tech business to accelerate innovation across the life sciences sector, the delivery of clinical trials and better health outcomes

Digital Health Global

With long-term backing from AstraZeneca and strategic collaborations with Parexel and Fortrea, Evinova offers globally-scaled digital products and services to the life sciences and healthcare sector. However, they are vital to the drug development and approval process and critical in enabling access to innovative medicines.